Olaptesed pegol: Additional Phase IIa data

Data from 20 evaluable patients with relapsed CLL in an open-label, dose-escalation, European Phase IIa trial showed that olaptesed pegol in combination with bendamustine and rituximab led to an ORR of 85%, including 4 complete responses and 13 partial responses. The trial has enrolled 28 patients. Data were presented at the European Hematology Association meeting in Milan. Noxxon previously reported interim data from 9 evaluable patients (see BioCentury, Jan. 13). Olaptesed pegol is also in Phase IIa testing to treat multiple myeloma (MM). ...